[A case of bronchial carcinoma showing regression upon intratumoral administration of OK-432].
A 38-year-old female suffering from chronic respiratory symptoms due to lung cancer occupying the left main bronchus was treated by frequent intratumoral injections of OK-432. The immune-modifying therapy was performed as follows; 0.2 KE of OK-432 was injected intracutaneously once a week, then the dose was gradually increased to 3.0 KE once a week. Following immunization, intratumoral injection was done under endoscopy at a dose of 3.0 KE every two weeks. Three months later, the tumor showed remarkable regression, and clinical symptoms were diminished. In conclusion, intratumoral injection of OK-432 was considered to be very beneficial in lung cancer.
Onodera
A
A
2nd Dept. of Internal Medicine, School of Medicine, University of Akita.
Miura
K
K
Sasaki
M
M
Sugiyama
N
N
Kurokawa
H
H
Shioya
T
T
Kanazawa
T
T
D000328:Adult; D001688:Biological Products / Q000008:administration & dosage*; D001984:Bronchial Neoplasms / Q000628:therapy*; D001999:Bronchoscopy; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D005260:Female; D006801:Humans; D010844:Picibanil / Q000008:administration & dosage* / Q000627:therapeutic use; D012074:Remission Induction
D001688:Biological Products; D010844:Picibanil